CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 32 enrolled
Drug / intervention
Testosterone gel +5 moredrug
Likely dose
Testosterone gel 10 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00490555
NCT00490555Phase 3Completed

The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men

University of Washington·interventional·Posted Jun 22, 2007·Updated Nov 15, 2013

In Brief

A Phase 3 clinical trial evaluating Testosterone gel, Dutasteride, and 4 other interventions for Healthy. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The investigators propose to examine the in vivo responses to hormonal manipulation at the molecular level directly in the tissue of interest (prostate). As in the investigators' previous, pilot study, the investigators will use the novel approach of procuring tissue specimens from normal, healthy men who might be chose to use a male hormonal contraceptive regimen were it available. The investigators will employ state of the art techniques such as laser capture microdissection (LCM) and cDNA microarrays to determine the tissue-specific consequences of male hormonal contraceptive regimens on the prostate. The results will help guide the design, safety monitoring, and selection of male hormonal contraceptive agents and provide valuable insights into prostate human prostate biology. The investigators will test the hypothesis that exogenous T administration that results in increased circulating T and dihydrotestosterone (DHT) levels will increase intraprostatic concentrations of T and its metabolite DHT. The investigators will test the hypothesis that the addition of a potent 5α-reductase inhibitor, dutasteride, or the progestin, Depomedoxyprogesterone (IM DMPA), to T administration in young and middle aged men will decrease intraprostatic DHT and increase intraprostatic T concentrations compared to T alone. The investigators will test the hypothesis that the addition of a 5α-reductase inhibitor dutasteride or the progestin IM DMPA to exogenous T, by reducing intraprostatic DHT, will decrease prostate epithelial proliferation, assessed by Ki-67 labeling index (Ki-67LI), and increase apoptosis, assessed by caspase-3 expression, and decrease androgen-regulated protein expression such as prostate specific antigen (PSA). The investigators will test the hypothesis that the addition of a 5α-reductase inhibitor or the progestin IM DMPA to exogenous T, by modifying the intraprostatic hormonal milieu, will alter prostate epithelial gene expression. Specifically, the investigators expect that the addition of the 5α-reductase inhibitor dutasteride or the progestin IM DMPA to exogenous T, will result in decreased expression of androgen-regulated genes such as PSA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 22, 2007
Enrollment StartJan 1, 2009
Primary CompletionJan 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.0 years ago

Interventions

Testosterone geldrug

Testosterone gel 10 g

Dutasteridedrug

dutasteride 0.5 mg orally

Depo-Medroxyprogesterone (DMPA)drug

300 mg DMPA injection on Day 0 IM (into the muscle)

Placebo Testosterone gelother

Place gel applied daily for 12 weeks

Placebo dutasterideother

placebo pill for 12 weeks

Placebo DMPAother

placebo DMPA injection Once